These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26645957)

  • 1. Dengue virus infection-enhancing antibody activities against Indonesian strains in inhabitants of central Thailand.
    Yamanaka A; Oddgun D; Chantawat N; Okabayashi T; Ramasoota P; Churrotin S; Kotaki T; Kameoka M; Soegijanto S; Konishi E
    Microbes Infect; 2016 Apr; 18(4):277-84. PubMed ID: 26645957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of Flavivirus Neutralizing Antibodies in Thailand by High-Throughput Neutralization Assay: Endemic Circulation of Zika Virus before 2012.
    Yamanaka A; Matsuda M; Okabayashi T; Pitaksajjakul P; Ramasoota P; Saito K; Fukasawa M; Hanada K; Matsuura T; Muramatsu M; Shioda T; Suzuki R
    mSphere; 2021 Aug; 6(4):e0033921. PubMed ID: 34259560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue virus infection-enhancing and neutralizing antibody balance in children of the Philippines and Indonesia.
    Yamanaka A; Tabuchi Y; Mulyatno KC; Susilowati H; Hendrianto E; Soegijanto S; Konishi E
    Microbes Infect; 2012 Nov; 14(13):1152-9. PubMed ID: 22841680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
    Yamanaka A; Suzuki R; Konishi E
    Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients.
    Yamanaka A; Moi ML; Takasaki T; Kurane I; Konishi E
    J Gen Virol; 2017 Feb; 98(2):166-172. PubMed ID: 27911254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.
    Ly MHP; Moi ML; Vu TBH; Tun MMN; Saunders T; Nguyen CN; Nguyen AKT; Nguyen HM; Dao TH; Pham DQ; Nguyen TTT; Le TQM; Hasebe F; Morita K
    BMC Infect Dis; 2018 Jan; 18(1):31. PubMed ID: 29321001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus).
    Azami NAM; Moi ML; Ami Y; Suzaki Y; Lim CK; Taniguchi S; Saijo M; Takasaki T; Kurane I
    Virol J; 2018 Mar; 15(1):51. PubMed ID: 29587780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection].
    Hu D; Li J; Wang D; DI B; Qiu L; Wang Y; Ding X; Che X
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1773-6, 1791. PubMed ID: 23268408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-existing cross-reactive antibodies on cyclic dengue outbreaks in the hyperendemic region of Bali, Indonesia.
    Balingit JC; Denis D; Suzuki R; Hayati RF; Ngwe Tun MM; Takamatsu Y; Masyeni S; Sasmono RT; Morita K
    Virus Res; 2024 Oct; 348():199445. PubMed ID: 39089369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.
    de Teive E Argolo AF; de Rezende Féres VC; Cordeiro MT; da Silveira LA; Guilarde AO; de Azevedo Marques ET; de Souza WV; Martelli CM
    BMC Infect Dis; 2016 Oct; 16(1):546. PubMed ID: 27717314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies.
    Buddhari D; Aldstadt J; Endy TP; Srikiatkhachorn A; Thaisomboonsuk B; Klungthong C; Nisalak A; Khuntirat B; Jarman RG; Fernandez S; Thomas SJ; Scott TW; Rothman AL; Yoon IK
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3230. PubMed ID: 25329173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of infection-neutralizing and -enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice.
    Sjatha F; Takizawa Y; Kotaki T; Yamanaka A; Konishi E
    Microbes Infect; 2013 Nov; 15(12):828-36. PubMed ID: 23911844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia.
    Sasmono RT; Taurel AF; Prayitno A; Sitompul H; Yohan B; Hayati RF; Bouckenooghe A; Hadinegoro SR; Nealon J
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006616. PubMed ID: 29953438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serologic and Virologic Studies of an Imported Dengue Case Occurring in 2014 in Okinawa, Japan.
    Saito M; Tamayose M; Miyagi K; Takaragawa H; Tateyama M; Tadano M; Fujita J
    Jpn J Infect Dis; 2016; 69(1):60-5. PubMed ID: 26073738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Persistence of Maternal Dengue Neutralizing Antibodies in Infants From Central and Southern Thailand: A Retrospective Cohort Study.
    Guignard A; Haguinet F; Wéry S; Kerdpanich P
    Asia Pac J Public Health; 2019 May; 31(4):288-295. PubMed ID: 31307216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers.
    van Panhuis WG; Gibbons RV; Endy TP; Rothman AL; Srikiatkhachorn A; Nisalak A; Burke DS; Cummings DA
    J Infect Dis; 2010 Oct; 202(7):1002-10. PubMed ID: 20738205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.
    Messer WB; Yount B; Hacker KE; Donaldson EF; Huynh JP; de Silva AM; Baric RS
    PLoS Negl Trop Dis; 2012; 6(2):e1486. PubMed ID: 22389731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.